EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Agenus's enterprise value is $122.8 Mil.
Agenus's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $156.3 Mil. Therefore, Agenus's EV-to-Revenue for today is 0.79.
The historical rank and industry rank for Agenus's EV-to-Revenue or its related term are showing as below:
AGEN'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.59 Med: 8.19 Max: 54.1
Current: 0.79
During the past 13 years, the highest EV-to-Revenue of Agenus was 54.10. The lowest was 0.59. And the median was 8.19.
AGEN's EV-to-Revenue is ranked better than 88.36% of 1031
companies
in the Biotechnology industry
Industry Median: 7.7
vs AGEN: 0.79
As of today (2024-04-24), Agenus's stock price is $6.46.
Agenus's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $8.53. Therefore, Agenus's PS Ratio for today is 0.76.
Agenus EV-to-Revenue Historical Data
The historical data trend for Agenus's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Agenus's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, Agenus's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Agenus's EV-to-Revenue falls into.
Agenus's current Enterprise Value is $122.8 Mil.
Agenus's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $156.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agenus's share price for today is $6.46.
Agenus's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.53.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agenus EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Agenus's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGEN has been successfully added to your 